SE447629B - Till fast form overford farmaceutisk komposition innehallande cellveggskelett av nocardia rubra - Google Patents

Till fast form overford farmaceutisk komposition innehallande cellveggskelett av nocardia rubra

Info

Publication number
SE447629B
SE447629B SE7808414A SE7808414A SE447629B SE 447629 B SE447629 B SE 447629B SE 7808414 A SE7808414 A SE 7808414A SE 7808414 A SE7808414 A SE 7808414A SE 447629 B SE447629 B SE 447629B
Authority
SE
Sweden
Prior art keywords
oil
cvs
rubra
mice
bound
Prior art date
Application number
SE7808414A
Other languages
English (en)
Swedish (sv)
Other versions
SE7808414L (sv
Inventor
Yuichi Yamamura
Ichiro Azuma
Katsusuke Ennyu
Osamu Aoki
Original Assignee
Yuichi Yamamura
Ichiro Azuma
Katsusuke Ennyu
Osamu Aoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuichi Yamamura, Ichiro Azuma, Katsusuke Ennyu, Osamu Aoki filed Critical Yuichi Yamamura
Publication of SE7808414L publication Critical patent/SE7808414L/xx
Publication of SE447629B publication Critical patent/SE447629B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE7808414A 1977-08-09 1978-08-04 Till fast form overford farmaceutisk komposition innehallande cellveggskelett av nocardia rubra SE447629B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9587177A JPS5428813A (en) 1977-08-09 1977-08-09 Solid preparation containing cell membrane extract substance used as suspension when using same

Publications (2)

Publication Number Publication Date
SE7808414L SE7808414L (sv) 1979-02-10
SE447629B true SE447629B (sv) 1986-12-01

Family

ID=14149407

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7808414A SE447629B (sv) 1977-08-09 1978-08-04 Till fast form overford farmaceutisk komposition innehallande cellveggskelett av nocardia rubra

Country Status (15)

Country Link
US (1) US4543253A (fi)
JP (1) JPS5428813A (fi)
AU (1) AU526788B2 (fi)
BE (1) BE869610A (fi)
CA (1) CA1118348A (fi)
CH (1) CH643459A5 (fi)
DE (1) DE2834893A1 (fi)
DK (1) DK153443C (fi)
FI (1) FI65370C (fi)
FR (1) FR2399844A1 (fi)
GB (1) GB2002229B (fi)
HU (1) HU179726B (fi)
IT (1) IT1098381B (fi)
NL (1) NL7808337A (fi)
SE (1) SE447629B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DD273198A5 (de) * 1986-06-09 1989-11-08 �������@�������k���Kk�� Verfahren zur herstellung eines modifikationsmittels
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US7534443B1 (en) * 1998-07-16 2009-05-19 Ichiro Azuma Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
EP1547607A4 (en) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co PREPARATION OF A COMPONENT OF BACTERIA CELL WALL SKELETON
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
CN115300490B (zh) * 2021-05-07 2024-04-16 安徽远望乐桓药业有限公司 包含角鲨烯和甘露醇的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185623A (en) * 1960-05-31 1965-05-25 Smith Fred Preservation of animal semen
US3177117A (en) * 1961-12-26 1965-04-06 Joseph F Saunders Process for freezing blood
FR2268531B1 (fi) * 1974-04-25 1978-07-21 Anvar
BE830486A (fr) * 1974-06-20 1975-12-22 Fractions mycobacteriennes utilisables comme agent antiinfectieux, et procede de preparation
FR2345158A1 (fr) * 1976-03-26 1977-10-21 Anvar Agents mitogenes, provenant notamment de peptidoglycanes bacteriens
FR2345159A2 (fr) * 1976-03-26 1977-10-21 Anvar Agents solubles dans l'eau ayant des proprietes mitogenes et/ou immuno-stimulantes, obtenus a partir de cellules de nocardia, et leurs procedes de preparation

Also Published As

Publication number Publication date
HU179726B (en) 1982-11-29
JPS631291B2 (fi) 1988-01-12
IT1098381B (it) 1985-09-07
DK352578A (da) 1979-02-10
GB2002229A (en) 1979-02-21
IT7826609A0 (it) 1978-08-08
DE2834893A1 (de) 1979-02-22
SE7808414L (sv) 1979-02-10
CA1118348A (en) 1982-02-16
DK153443B (da) 1988-07-18
GB2002229B (en) 1982-05-26
CH643459A5 (de) 1984-06-15
NL7808337A (nl) 1979-02-13
AU526788B2 (en) 1983-02-03
DK153443C (da) 1988-12-05
JPS5428813A (en) 1979-03-03
FR2399844A1 (fr) 1979-03-09
FR2399844B1 (fi) 1982-08-20
FI65370C (fi) 1984-05-10
FI65370B (fi) 1984-01-31
FI782442A (fi) 1979-02-10
AU3879178A (en) 1980-02-14
US4543253A (en) 1985-09-24
BE869610A (fr) 1979-02-08
DE2834893C2 (fi) 1987-08-27

Similar Documents

Publication Publication Date Title
US4877611A (en) Vaccine containing tumor antigens and adjuvants
Shimada et al. Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors
US6375945B1 (en) Adjuvant compositions for vaccines
EP0752870B1 (en) Use of mycobacterium for the treatment of tumours
KR101124363B1 (ko) 면역조절곤란증을 포함하는 질병을 치료하기 위한 그람양성균 제제
SE447629B (sv) Till fast form overford farmaceutisk komposition innehallande cellveggskelett av nocardia rubra
YAMAWAKI et al. Antitumor activity of squalene-treated cell-wall skeleton of Nocardia rubra in mice
US4504473A (en) Pyridine soluble extract of a microorganism
JP4371437B2 (ja) 悪性腫瘍の治療方法
US5336666A (en) Immunostimulant drug based on polar glyopeptidolipids of mycobacterium chelonae
KR101146469B1 (ko) 다른 약물과 공동으로 결핵의 복합 치료에 유용한면역치료제
Butler et al. Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants
US4505903A (en) Pyridine soluble extract of a microorganism
JPH0737479B2 (ja) ムラミルジペプチド誘導体
Dinney et al. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or γ-interferon
Kobayashi et al. In vitro and in vivo comparisons of amphotericin B and ND-ornithyl amphotericin B methyl ester
CA1206416A (en) Pyridine soluble extract of a microorganism
GB2122897A (en) Treatment of cancer with microorganism obtained products
KR820000420B1 (ko) 세포의 벽조직을 구성하는 고형화된 제약 조성물의 제조방법
Schindler et al. Stimulatory effects of muramyl dipeptide and its butyl ester derivative on the proliferation and activation of macrophages in vitro
GB2120548A (en) Anti-tumour microorganism obtained products
磯貝浩 et al. Biological effects of lipopolysaccharide from Achromobacter stenohalis on lymphocytes and macrophages.
GB2411357A (en) Vaccine for fish cold-water disease
GB2123006A (en) Pyridine soluble extract of a microorganism
Okamoto et al. Toll-like receptor-targeting immunotherapy for oral cancer

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7808414-2

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7808414-2

Format of ref document f/p: F